Summary of Lucid Diagnostics (LUCD) Q1 2026 Earnings Call

1Key Financial Results and Metrics

Tests Performed: 3,177 EsoGuard tests conducted in Q1 2026, slightly down from Q4 2025.

Revenue: Generated $1.3 million in revenue, reflecting a decrease proportional to test volume but above the target range of 2,500 to 3,000 tests.

Cash Position: Cash at the end of Q1 was $27.9 million, with pro forma cash (including recent financing) at approximately $44.8 million.

Burn Rate: Average cash burn rate was $12.1 million for Q1, slightly higher than the previous four-quarter average of $11.3 million.

Net Loss: Non-GAAP net loss per share improved to $0.07, a $0.03 improvement from the previous three quarters.

2Strategic Updates and Business Highlights

Medicare Approval Focus: The company is actively engaged in the Medicare Local Coverage Determination (LCD) process, acknowledging delays but maintaining confidence in a positive outcome.

VA Engagement: Strong progress with Veterans Affairs (VA) systems, with initial purchase orders expected soon. The VA represents approximately 9 million covered lives.

Commercial Payer Activity: Ongoing discussions with commercial payers, with some showing interest in EsoGuard as a triage test for endoscopy.

Clinical Evidence Generation: Continued commitment to generating clinical data, including ongoing studies and registry activities, to support future reimbursement and market expansion.

3Forward Guidance and Outlook

Operational Plans: The company plans to maintain its current cash burn rate while investing in commercial efforts, particularly in anticipation of Medicare approval.

Revenue Growth Potential: Medicare coverage could significantly impact revenue recognition, as it affects 40-50% of the addressable patient population.

Sales Team Strategy: The sales team is focused on increasing the proportion of Medicare patients while managing overall test volume without significantly increasing operational expenses.

4Bad News, Challenges, or Points of Concern

Revenue Decline: Revenue decreased despite performing more tests, indicating challenges in reimbursement collection.

Medicare Delays: Ongoing frustrations regarding the delays in the Medicare LCD process could hinder growth and revenue recognition.

Market Competition: The company faces competitive pressures in the molecular diagnostics space, particularly as it seeks to expand its payer relationships.

5Notable Q&A Insights

Medicare Engagement: Management remains optimistic about Medicare discussions, viewing current delays as logistical rather than substantive concerns.

VA System Integration: The company is actively working with VA centers, leveraging a federal supply schedule to facilitate engagement.

Commercial Payer Dynamics: Some commercial payers are waiting for Medicare decisions before moving forward, but others are actively engaging with Lucid Diagnostics.

Sales Force Productivity: The productivity of the sales team is reported to be solid, with a focus on balancing existing test volume and new opportunities, particularly within the VA system. Overall, Lucid Diagnostics is navigating a transitional period with a focus on expanding its market presence while awaiting critical Medicare approval, which is expected to significantly impact its financial performance moving forward.